MedTrace Logo

Safety and Efficacy Evaluation of ET-01 Transplantation in Subjects With Transfusion Dependent β-Thalassaemia

NCT04390971 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2026-02-11

No results posted yet for this study

Summary

This is an open label, multi-center study to evaluate the safety and Efficacy of ET-01 Transplantation in subjects with Transfusion Dependent β-Thalassaemia.

Conditions

  • Transfusion Dependent Beta-Thalassaemia

Interventions

BIOLOGICAL

ET-01

Recruited participants will receive ET-01 IV infusion after conditioning.

Sponsors & Collaborators

  • EdiGene Inc.

    collaborator INDUSTRY

  • The Affiliated Hospital Of Guizhou Medical University

    collaborator OTHER

  • Zunyi Medical College

    collaborator OTHER

  • Institute of Hematology & Blood Diseases Hospital, China

    lead OTHER

Principal Investigators

  • Jun Shi, PhD · Institute of Hematology & Blood Diseases Hospital, China

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
6 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-10
Primary Completion
2023-03-05
Completion
2023-03-05

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04390971 on ClinicalTrials.gov